Analyst Increases Price Target for Madrigal Pharmaceuticals Maintains Strong Buy Recommendation
According to Citigroup analyst David Lebovitz, Madrigal Pharmaceuticals (NASDAQ: MDGL) continues to be a strong buy as of March 15, ...
According to Citigroup analyst David Lebovitz, Madrigal Pharmaceuticals (NASDAQ: MDGL) continues to be a strong buy as of March 15, ...
Madrigal Pharmaceuticals shares are on the rise following an increase in price target by HC Wainwright & Co. to $405. ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.